Home » Newsletters » BioWorld Science

BioWorld Science

July 23, 2018

View Archived Issues

Positive data presented from SEQUOIA and CEDAR phase III studies of abicipar

Transgenic mouse model useful to study the hypersensitivity reactions of abacavir

Phase IIa study of BT-063 for the treatment of SLE meets primary endpoint

Gritstone Oncology to test GRANITE-001 with Opdivo and Yervoy

Membrane findings point to new antimalarial strategies

Sending live phages after deadly lung infections

The Yang to KRAS' Yin?

First biomarker for liver injury from biologic

AT: all bad for platelets

Aevi presents AEVI-004, novel co-crystal version of AEVI-001

UCT-943, a next-generation PI4K inhibitor antimalarial agent: Preclinical profile

Wakamoto completes phase II trial of WP-1303

BeiGene reports preliminary phase II topline data for tislelizumab in classical Hodgkin's lymphoma

FDA grants approval to Tibsovo for relapsed/refractory AML with IDH1 mutation

UCB Pharma divulges UDP/CysLT receptor modulators

Researchers find IL-6 levels tied to worse prognosis in ESCC patients

New G protein-coupled receptor 39 agonists patented by Daiichi Sankyo

INSERM and collaborators describe lactic acid bacteria compositions

Samsung Life Public Welfare Foundation creates siRNAs specific to the SS18-SSX fusion gene

ShanghaiTech University synthesizes PIWIL4 inhibitors

New phase I study evaluates MK-4830 alone and with pembrolizumab for advanced solid tumors

FDA approves single-dose Krintafel for radical cure of P. vivax malaria

Asceneuron presents phase I results for ASN-120290

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 13, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.